Description:
Background
 
DNA adducts are damaged nucleotides in DNA as a consequence of its exposure to genotoxic agents or conditions. Measurement of multiple DNA adducts in a single procedure is referred to as “DNA adductomics”. In the leading analytical technique for this purpose, typically the following sequence of steps takes place starting with a biosample: 
- Isolate the DNA
- Digest it to deoxynucleosides enzymatically
- Remove the enzymes and inject into a UPLC-tandem mass spectrometer using CID conditions that release the sugar as a neutral
- Observe peaks for adducts as protonated nucleobases
While this method is highly successful as has been reviewed, it has some shortcomings, mainly: 
- Adduct sensitivity can vary widely for different adducts
- Though useful for bulky adducts, simultaneous detection of polar adducts is limited since they tend to elute in the early noise-intense region of reversed-phase liquid chromatography, much before most bulky adducts
P-postlabeling is a technique that has been widely employed for many years and can provide very high sensitivity. Its major disadvantages are that the yield of the labeling reaction is adduct dependent; it is difficult to incorporate internal standards, and it is not easy to establish the identity of a radioactive adduct spot.
 
Technology Overview
 
Northeastern University researchers introduced a new technique for DNA adductomics they refer to as “Mass Tag Pre-labeling”. This name was selected since this method shares the feature of labeling with 32P-postlabeling. Also, there are two contrasts: labeling in this technique is done with a mass tag rather than a radiolabel, and the labeling is done prior to enzymatic digestion of the DNA to nucleotides. 
 
Benefits
 
- Other mass spectrometry techniques only detect polar or nonpolar adducts at once
- Radiolabeling is nonspecific
- There is nowhere in the world currently where the people can send a sample of blood for a comprehensive DNA adductomics test
 
Applications
 
- Can be used in cell culture, animal, and clinical trials initially
- General use in clinical diagnostics as a cancer prevention test in the longer term
 
Opportunity
 
- License
- Partnering
- Research collaboration
Patent Information:
Category(s):
-Cancer
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
m.saulich@northeastern.edu
Inventors:
Roger Giese
Poguang Wang
Keywords:
Cancer
cancer prevention
DNA adduct
Mass Spectrometry
Mass tags
personalized medicine